Gerdes L U, Jürgensen H J, Groot P H, Faergeman O
Medical Department I, Aarhus County Hospital.
Acta Med Scand. 1988;223(5):419-22. doi: 10.1111/j.0954-6820.1988.tb15892.x.
The concentration of lipids, lipoproteins and apolipoprotein A-I and B was measured in the plasma of 33 patients, enrolled in a double-blind, controlled trial of alprenolol in myocardial infarction, after one year on the study medication and again after 6 months off the medication. Sixteen patients received 200 mg alprenolol twice daily and 17 received placebo. There were no statistically significant differences between the parameters in the two groups after one year on medication. However, when medication was stopped, the ratio of apolipoprotein B to apolipoprotein A-I fell by 9% in the alprenolol group and increased by 2% in the placebo group. This difference was statistically significant. Our results suggest that alprenolol, a beta-blocker with weak intrinsic sympathomimetic effect, has slight effects on plasma lipoproteins. These effects were apparent only by measurements of apolipoproteins.
在一项双盲、阿普洛尔治疗心肌梗死对照试验中，对33例患者血浆中的脂质、脂蛋白、载脂蛋白A-I和B进行了测量。这些患者在服用研究药物一年后以及停药6个月后再次接受检测。16例患者每日两次服用200毫克阿普洛尔，17例患者服用安慰剂。服药一年后，两组的参数之间无统计学显著差异。然而，停药后，阿普洛尔组载脂蛋白B与载脂蛋白A-I的比值下降了9%，而安慰剂组则上升了2%。这种差异具有统计学显著性。我们的结果表明，具有微弱内在拟交感神经效应的β受体阻滞剂阿普洛尔对血浆脂蛋白有轻微影响。这些影响仅通过载脂蛋白测量才能显现。
